Nuclear Medicine Is Big Pharma’s New Target in Cancer Race
- Perspective Therapeutics sees pickup in investors’ interest
- Biotechs work on injected radioactive drugs to target tumors
Prostate cancer visualized by ultrasound.
Source: BSIP/Universal Images Group Editorial/Getty Images
This article is for subscribers only.
As pharma giants spend billions on acquisitions of startups developing new ways to harness radiation in the fight against cancer, the chief executive officer of Perspective Therapeutics Inc. found himself getting top billing at two different industry gatherings this week.
The Seattle-based firm has seen its value roughly quadruple to $833 million this year, swept up in the radiopharmaceuticals frenzy. No wonder CEO Thijs Spoor was being sought out by investors at the events, one of which praised nuclear medicine’s disruptive potential.